NOVAN INC (NOVN)
(Delayed Data from NSDQ)
$1.22 USD
+0.07 (5.75%)
Updated May 3, 2019 03:59 PM ET
After-Market: $1.22 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.22 USD
+0.07 (5.75%)
Updated May 3, 2019 03:59 PM ET
After-Market: $1.22 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Top Ranked Momentum Stocks to Buy for April 2nd
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 2nd
Top Ranked Momentum Stocks to Buy for March 30th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, March 30th
Buy 5 Top-Ranked Stocks With Rising P/E
by Sanghamitra Saha
Inside the top-ranked stocks that have been exhibiting rising P/E ratios.
Top Ranked Momentum Stocks to Buy for March 11th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, March 11th
Actinium Treats First Patient in AML Study on Actimab-A Combo
by Zacks Equity Research
Actinium (ATNM) treats first patient in the third and final cohort of the Actimab-A and CLAG-M combination phase I study to treat relapsed or refractory acute myeloid leukemia.
Pacira's (PCRX) Q4 Earnings Top Estimates, Revenues In Line
by Zacks Equity Research
Pacira (PCRX) beats earnings estimates in the fourth quarter of 2019. Revenues are in line with estimates.
Company News For Jan 6, 2020
by Zacks Equity Research
Companies In The News Are: CANF, LW, INCY, NOVN
Analysts Estimate Novan (NOVN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Novan (NOVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Novan (NOVN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Novan (NOVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is WisdomTree International High Dividend Fund (DTH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DTH
Is WisdomTree International High Dividend Fund (DTH) a Strong ETF Right Now?
by Sweta Killa
Smart Beta ETF report for DTH
Is WisdomTree International High Dividend Fund (DTH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DTH
Will NOVAN INC (NOVN) Report Negative Q4 Earnings? What You Should Know
by Zacks Equity Research
NOVAN INC (NOVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is WisdomTree International High Dividend Fund (DTH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DTH
Is WisdomTree International High Dividend Fund (DTH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DTH
Is WisdomTree International High Dividend Fund (DTH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DTH
Novan Announces Top-Line Data From Mid-Stage Molluscum Study
by Zacks Equity Research
Novan's (NOVN) nitric oxide candidate, SB206, demonstrates statistically significant reduction of lesions in patients with molluscum contagiosum.
Is WisdomTree International High Dividend Fund (DTH) a Hot ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DTH
Is WisdomTree International High Dividend Fund (DTH) a Hot ETF Right Now?
by Sweta Killa
Smart Beta ETF report for DTH
Novan (NOVN) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Novan (NOVN) delivered earnings and revenue surprises of 15.63% and -4.00%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Novan (NOVN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Novan (NOVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is WisdomTree International High Dividend Fund (DTH) a Hot ETF Right Now?
by Sweta Killa
Smart Beta ETF report for DTH
Is WisdomTree International High Dividend Fund (DTH) a Hot ETF Right Now?
by Sweta Killa
Smart Beta ETF report for DTH
Novan Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Novan has been struggling lately, but the selling pressure may be coming to an end soon.
Is WisdomTree International LargeCap Dividend Fund (DOL) a Hot ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DOL